As part of its advocacy program in the United States, ACRO submits regulatory comments to U.S. regulators. This comment letter, submitted by ACRO to the FDA in 2026, in support of the development of a harmonized approach on the use, design, conduct, analysis and submission of patient preference studies (PPS), can be found below.